• News
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Presentations
    • The Share
      • Largest Shareholders
      • Rights Issue / Företrädesemission 2020
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
logo
  • News
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Presentations
    • The Share
      • Largest Shareholders
      • Rights Issue / Företrädesemission 2020
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
Home / General Meetings / Auditor
  • Overview
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • The Share
    • Share Monitor
    • Largest Shareholders
    • Rights Issue / Företrädesemission 2020
    • Previous Share Issuances
    • Analyst Coverage
  • Financial Reports
    • English
    • Swedish
  • Financial Calendar
  • Corporate Governance
    • General Meetings
    • Auditor
    • Articles of Association
    • Board of Directors
    • Management
  • Certified Adviser
  • IR Contact

Auditor

The company’s auditor, Ernst & Young AB, Gothenburg, was selected before the company was listed on Spotlight Stock Market. The current term for the period is until the end of the 2021 Annual General Meeting.
Andreas Mast is the auditor in charge, and Andreas is also a partner in Ernst & Young AB and their office manager.

Andreas has many years experience from leading and organizing large and medium size audit engagements, mainly with focus on listed companies and companies in international groups. Also several years experience from auditing companies within the Life Science sector.

Andreas is a member of FAR, the association of Swedish professional accountants.

Ernst & Young
Parkgatan 49
401 82 Göteborg

  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin